Carbamazepine-induced thrombocytopenia defined by a challenge test.
Carbamazepine (CBZ), a widely used anticonvulsant, occasionally causes serious hematologic disorders. A 12-year-old boy was admitted because of a diffuse petechial rash and profound thrombocytopenia (10 x 10(9) platelets/l), after having been treated for epilepsy with CBZ for 12 days. Seven days following withdrawal of CBZ and initiation of prednisolone therapy, the platelet count recovered. In a subsequent challenge test with CBZ, platelet counts again decreased, and the levels of platelet-associated IgG and serum interleukin-6 increased. No antibodies against platelet glycoprotein IIb/IIIa or Ib were detected in plasma. We believe that this is the first reported occasion when CBZ-induced thrombocytopenia has been defined by a rechallenge test.
Ishikita
T
T
Department of Pediatrics, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Japan.
Ishiguro
A
A
Fujisawa
K
K
Tsukimoto
I
I
Shimbo
T
T
D000927:Anticonvulsants / Q000009:adverse effects*; D001772:Blood Cell Count / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis; D002220:Carbamazepine / Q000009:adverse effects*; D002648:Child; D003228:Conjunctiva / Q000098:blood supply; D004802:Eosinophilia / Q000139:chemically induced*; D004828:Epilepsies, Partial / Q000188:drug therapy; D005334:Fever / Q000139:chemically induced*; D005483:Flushing / Q000139:chemically induced; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D007124:Immunoenzyme Techniques; D015850:Interleukin-6 / Q000097:blood; D007964:Leukocytosis / Q000139:chemically induced*; D008297:Male; D011693:Purpura / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis
D000927:Anticonvulsants; D015850:Interleukin-6; D002220:Carbamazepine; D002097:C-Reactive Protein